Skip to main content
. 2019 May 21;10(6):398. doi: 10.1038/s41419-019-1628-8

Fig. 5. Combination of perifosine and Olaparib synergistically represses triple-negative breast cancer growth in vivo.

Fig. 5

a, b Mice bearing MDA-MB-231 xenografts were treated with vehicle control, perifosine (1 mg/kg, t.i.d.), olaparib (50 mg/kg/, t.i.d), or their combination. Tumor growth curve (a) and tumor weight (b) are shown. Data presented as mean ± s.d. of eight mice per group. c Body weight of mice treated with control (Ctrl), 1 mg/kg perifosine, 50 mg/kg Olaparib, or their combination. d Serum analysis including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of mice after various treatment. Data presented as mean ± s.d. of three replicates. e Hematoxylin and eosin staining of liver and kidney organs after various treatments (×20). f Western blot analysis of γ-H2AX, Chk1, p-Chk1, Akt, p-Akt, FOXO1, p-FOXO1, GSK-3β, and p-GSK-3β levels in tumors of xenograft model. β-actin was used as a loading control. **P < 0.01, ***P < 0.001, and n.s. no significance